First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 15.43 USD 3.14% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

DNLI Price Targets Summary
Denali Therapeutics Inc

Wall Street analysts forecast DNLI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNLI is 42.01 USD with a low forecast of 24.24 USD and a high forecast of 99.75 USD.

DNLI Lowest Forecast
Wall Street Target
24.24 USD
57% Upside
DNLI Average Forecast
Wall Street Target
42.01 USD
172% Upside
DNLI Highest Forecast
Wall Street Target
99.75 USD
546% Upside
Lowest
Price Target
24.24 USD
57% Upside
Average
Price Target
42.01 USD
172% Upside
Highest
Price Target
99.75 USD
546% Upside
Denali Therapeutics Inc Competitors:
Price Targets
300406
Beijing Strong Biotechnologies Inc
24% Upside
ABBV
Abbvie Inc
18% Upside
Z
ZVSA
Zyversa Therapeutics Inc
64% Upside
OXB
Oxford BioMedica PLC
86% Upside
300406
Beijing Strong Biotechnologies Inc
24% Upside
ABBV
Abbvie Inc
18% Upside
Z
ZVSA
Zyversa Therapeutics Inc
64% Upside
OXB
Oxford BioMedica PLC
86% Upside
KYMR
Kymera Therapeutics Inc
57% Upside
LYEL
Lyell Immunopharma Inc
182% Upside
KRON
Kronos Bio Inc
334% Upside
RYTM
Rhythm Pharmaceuticals Inc
57% Upside

Revenue
Forecast

Revenue Estimate
Denali Therapeutics Inc

The compound annual growth rate of Denali Therapeutics Inc's revenue for the next 3 years is -10%.

N/A
Past Growth
-10%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Denali Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Denali Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
DNLI intrinsic value, competitors valuation, and company profile.
DCF Valuation
DNLI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DNLI stock valuation using valuation multiples.
Wall Street Estimates
DNLI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DNLI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DNLI's stock price target?
Price Target
42.01 USD

According to Wall Street analysts, the average 1-year price target for DNLI is 42.01 USD with a low forecast of 24.24 USD and a high forecast of 99.75 USD.

What is Denali Therapeutics Inc's Revenue forecast?
Projected CAGR
-10%

The compound annual growth rate of Denali Therapeutics Inc's revenue for the next 3 years is -10%.

ALPHA SPREAD
Join more than 132,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.